Current Report Filing (8-k)
July 22 2019 - 4:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________
FORM 8-K
_______________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): July 22, 2019
_______________
Protalix
BioTherapeutics, Inc.
(Exact name of registrant as specified
in its charter)
_______________
Delaware
|
|
001-33357
|
|
65-0643773
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
2 Snunit Street
|
|
20100
|
Science Park, POB 455
|
|
|
Carmiel, Israel
|
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area
code +972-4-988-9488
(Former name or former address, if changed
since last report.)
_______________
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction
A.2. below):
|
¨
|
Written communication pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title
of each class
|
Trading
Symbol(s)
|
Name of
each exchange on which registered
|
common stock, $0.001 par value
|
PLX
|
NYSE American
|
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
Item
5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
|
On July 22, 2019, Protalix BioTherapeutics, Inc. (the “Company”)
announced that Yossi Maimon notified the Company of his resignation from his position as the Company’s Vice President and
Chief Financial Officer to pursue other opportunities. The Company intends to appoint a new chief financial officer soon. Until
his departure, Mr. Maimon will work together with the Company’s finance and accounting teams to ensure a smooth transition
of the Company’s financial and accounting functions, pending the Company’s appointment of his successor.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 22, 2019
|
PROTALIX
BIOTHERAPEUTICS, INC.
|
|
|
|
By:
|
/s/
Dror Bashan
|
|
|
Name:
|
Dror Bashan
|
|
|
Title:
|
President and
Chief Executive Officer
|
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Sep 2023 to Sep 2024